Pediatric Multisystem Inflammatory Disease and COVID-19


Until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care

The article, “The Relationship Characteristics of Pediatric Multisystem Inflammatory Disease and COVID-19,” was originally published on ContagionLive.

Coronavirus disease 2019 (COVID-19)-associated multisystem inflammatory syndrome (MIS-C) in children leads to serious and life-threatening illness in otherwise healthy children and teens.

Investigators from the US Centers for Disease Control and Prevention (CDC) and Boston Children’s Hospital prospectively and retrospectively tracked MIS-C and COVID-19 data from March 15 to May 20, 2020 to summarize what is known about the illnesses’ relationship. Their 6 criteria included serious illness leading to hospitalization, age under 21 years, fever that lasted longer than 24 hours, laboratory-confirmed evidence of inflammation, multisystem organ involvement, and evidence of COVID-19 infection based on PCR or antibody testing or exposure to another person with COVID-19 in the past month.

Children with this hyperinflammatory syndrome present similar to those with Kawasaki disease, the study authors wrote, and it is similar to MIS-C in that it has no diagnostic confirmation tests.

There were 186 cases of MIS-C reported to the Overcoming COVID-19 study and the CDC by clinicians from 26 states, the study authors said. The median age of the patients was about 8 years, there were 115 male patients, and three-quarters of the group had previously been healthy. Additionally, the study authors reported that 19% were white, 25% were Black, 5% were another race, 31% were Hispanic or Latino, and 22% race was unknown.

The majority of those patients were hospitalized in the second half of the study period, from April 16 to May 20, the study authors added, noting the peak incidence of MIS-C occurred when COVID-19 activity was decreasing. Most of the COVID-19 cases were confirmed by PCR testing, antibody testing, or both, and about half could be linked to another person with the infection.

The study authors also identified 14 patients with recorded COVID-19 symptoms prior to the onset of MIS-C. They said the median interval from COVID-19 symptom onset to MIS-C symptom onset was 25 days.

Three-quarters of COVID-19 patients had involvement of at least 4 organ systems, the study authors said, and they were most often the gastrointestinal, cardiovascular, hematologic, mucocutaneous, and respiratory systems. The majority of patients were treated in the ICU and 20% received invasive mechanical ventilation, the investigators reported. At the end of the observation period, the study authors said 130 patients had been discharged alive, 52 remained hospitalized, and 4 patients died. The patients who died were all between ages 10 and 16, and additionally, 2 had underlying conditions, the study authors said.

Of the MIS-C patients, a majority had a fever for more than 5 days, the investigators said, and almost all of them had a fever for more than 4 days. Cardiovascular involvement was common in 4 out of 5 patients and 90 patients received vasoactive support, the study authors wrote. There was respiratory insufficiency or respiratory failure present in 109 patients, of which 85 had no underlying respiratory conditions, they added. From that group, 37 patients received invasive mechanical ventilation and 32 patients received noninvasive mechanical ventilation.

Most patients also had 4 or more laboratory markers that indicated inflammation, the study authors said, including: C-reactive protein level, lymphocytopenia, neutrophilia, elevated ferritin level, hypoalbuminemia, elevated alanine aminotransferase level, anemia, thrombocytopenia and an elevated d-dimer level, prolonged international normalized ratio, or elevated fibrinogen level.

The investigators treated the MIS-C patients with immunomodulatory drugs such as intravenous immune globulin (77%) and systemic glucocorticoids (49%), they wrote.

The study authors suggested that until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care.

“The clinical and the laboratory features of hyperinflammation, the timing of onset in relation to SARS-CoV-2 infection, and the similarities with the disease pattern in adults with Covid-19 support the hypothesis that MIS-C is a consequence of immune-mediated injury triggered by SARS-CoV-2 infection,” the study authors concluded.

The study, “Multisystem Inflammatory Syndrome in U.S. Children and Adolescents,” was published online in The New England Journal of Medicine.

Related Videos
A Promising Pipeline for COPD
Projecting Dupilumab's Fit in COPD
What the Ensifentrine FDA Approval Means for COPD
Pavel Strnad, MD | Credit: RWTH Aachen
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.